RSV disease in infants and young children: Can we see a brighter future?

Area of Science:

• Pediatrics
• Virology
• Immunology

Background:

• Respiratory syncytial virus (RSV) is a primary cause of severe Lower Respiratory Tract Infections (LRTI) in children under five.
• RSV infection leads to approximately 3 million hospitalizations and 120,000 deaths globally each year, disproportionately affecting infants.
• Current preventive options are limited, with only one monoclonal antibody approved for a select group, highlighting a significant unmet medical need.

Purpose of the Study:

• To review the current landscape of RSV prevention strategies.
• To highlight the urgent need for novel approaches to combat RSV burden in children.
• To emphasize the potential of new technologies in addressing RSV as a leading cause of pediatric hospitalization.

Main Methods:

• Literature review of existing and emerging RSV prevention methods.
• Analysis of RSV epidemiology and global health impact.
• Exploration of technological advancements in vaccine and antibody development.

Main Results:

• Existing preventive measures for RSV are insufficient to meet global demand.
• Several promising approaches are under development, including maternal vaccines, extended half-life monoclonal antibodies, and pediatric vaccines.
• New technologies offer a promising pathway to effectively address the significant burden of RSV.

Conclusions:

• There is a critical need for broader and more effective preventive strategies against RSV for all children.
• Ongoing research and development in vaccines and monoclonal antibodies are crucial.
• Technological innovation is key to overcoming the global challenge posed by RSV in pediatric populations.